Core Insights - WuXi Biologics has achieved a historic record by winning six awards and two individual leadership awards at the 2026 Asia-Pacific Biopharma Excellence Awards, highlighting its leadership in bioprocessing, manufacturing, and digital innovation [1] Group 1: Awards and Recognition - The company won in categories such as Excellence in Bioprocessing Automation & Digitalization, Bioprocessing Facility of the Year, and Best Contract Development & Manufacturing Organization Award [1] - Dr. Sherry Gu was named CTO of the Year, and Dr. Jeremy Guo received the award for Head of Fill-Finish & Formulation of the Year, recognizing their contributions to biologics development and manufacturing [1] Group 2: Business Operations and Achievements - WuXi Biologics operates 945 integrated projects, with nearly 50% involving bi- and multi-specific antibodies and ADCs, making it one of the largest portfolios of complex biologics globally [1] - The company has achieved a 100% success rate in PPQ campaigns and delivered over 350 large-scale batches (6,000 L – 16,000 L per batch) since 2017 [1] - WuXi Biologics has passed 46 regulatory inspections, including 22 by the FDA and EMA, maintaining a 100% pass rate for FDA Pre-License Inspection [1] Group 3: Technological Innovations - The company launched WuXia™ TrueSite, achieving average mAb titers over 8.0 g/L, and advanced its high-dose delivery technologies, enabling protein concentrations of up to 230 mg/mL [1] - WuXi Biologics has integrated digital innovation across R&D and manufacturing, achieving approximately 40% productivity gains and a 20% improvement in efficiency through advanced planning systems [1] Group 4: Sustainability and ESG Commitment - WuXi Biologics emphasizes sustainability as a cornerstone of long-term growth, driving green technology innovations and achieving excellence in Environment, Social, and Governance (ESG) practices [2]